Another top exec leaves J&J unit; Lilly gets fibromyalgia use for Cymbalta;

> Worldwide president of Johnson & Johnson's Cordis unit--the stent-maker--announced he's leaving the company as of July 11, becoming the seventh senior exec at Cordis to announce an exit in recent months. Report

> Eli Lilly has received governmental approval to use its anti-depression drug Cymbalta on a new class of patients: those with fibromyalgia. Report

> Struggling drug developer Skyepharma rallied as the US authorities gave approval to GlaxoSmithKline's once-a-day Parkinson's treatment Requip XL, which uses Skyepharma's technology.Report

> The FDA gave the nod to Lupin's version of the Forest Laboratories antidepressant Lexapro, for distribution post-patent in 2012. Report

> To restrain pharmaceutical companies from escaping price controls by tweaking the pack size and strength of their price-controlled brands, India has introduced "pro-rata pricing" to standardize costs across formulations and dosage strengths. Report

> Abbott has opened a new Formulation Development Center at its Illinois headquarters. At the R&D facility, researchers will take candidate molecules and formulate them into tablets and capsules for use in in pre-clinical and clinical studies. Report

> CRO Parexel has made a $182 million bid for U.K.-based ClinPhone, but it may be facing competition from Quintiles, the world's largest private CRO. Report

> As the battle for Biovail continues, current CEO William Wells emphasized the company's focus on CNS drug development at Goldman Sachs' annual healthcare conference. Biovail is investing $600 million over the next four years for work on epilepsy, multiple sclerosis, and Parkinson's. Report

> Outside experts are preparing to review ustekinumab, Centocor's injectable treatment for severe psoriasis. Report

> A recent report by Credit Suisse analysts found that investing in medical nanotechnology could have a real payoff in the coming years. Report

Emerging Drug Developer: Itero Biopharmaceuticals 

And Finally... High levels of the "hunger hormone" ghrelin have an antidepressant effect, researchers claim. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.